EDITEditas Medicine, Inc.
$2.83-28% 1Y
$2.83
$1.6652 weeks$4.15
EDIT in its own filings
Nothing in EDIT's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
198
Events found in the filings · across 726 filings · the record starts in 2015
- Hard flags
- none
Hard flags
- Most recent filing
- Oct 8, 2026
Most recent filing · Form 8-K
- Record starts
- Nov 16, 2015
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 9, 2026
- Change in certifying accountantpast_year
- 2026-04-07
- SEC comment-letter activity8 occurrences
- 2017-03-30
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 8, 2026On October 8, 2026, the Company announced that it has received approval to initiate the Phase 1/2 Strive™ clinical trial of EDIT-401 in patients with heterozygous familial hypercholesterolemia in Australia.Regulation FD disclosure · Form 8-K
- Aug 5, 2026On August 3, 2026, Elliott Levy, M.D., a member of the Board of Directors (the “Board”) of the Company who was serving as a class I director, resigned from the Board, effective August 4, 2026.Earnings release · Form 8-K
- May 26, 2026Public Offering On May 26, 2026, Editas Medicine, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co. and Wells Fargo Securities, LLC as representatives of the underwriters named therein (the “Underwriters”), relating to an underwritten public …Material agreement entered · Form 8-K
- May 26, 2026On May 26, 2026, Editas Medicine, Inc. (the “Company”) notified TD Securities (USA) LLC (“TD Cowen”) that it was suspending and terminating the prospectus supplement, dated March 21, 2025, related to the sales agreement that the Company entered into with TD Cowen on May 14, 2021, as amended on February 28, 2024 and on …Other event · Form 8-K
- May 26, 2026On May 25, 2026, the Company announced in an oral presentation at the 94 th European Atherosclerosis Society (EAS) Congress new preclinical data for EDIT-401, its lead in vivo development candidate, from preclinical studies in non-human primates (“NHPs”)Regulation FD disclosure · Form 8-K
- May 14, 2026On May 14, 2026, at the 2026 Annual Meeting of the American Society of Gene and Cell Therapy (“ASGCT”), the Company reported new preclinical data supporting the continued advancement of the Company’s lead in vivo development candidate, EDIT-401, and its potential as a one-time treatment for hyperlipidemia, as well as …Regulation FD disclosure · Form 8-K
- Apr 7, 2026Dismissal of Independent Registered Public Accounting Firm On April 1, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors of Editas Medicine, Inc. (the “Company”) (i) dismissed Ernst & Young LLP (“Ernst & Young”) as the Company’s independent registered public accounting firm, effective …Auditor change · Form 8-K
- Mar 27, 2026On March 26, 2026, the U.S. Patent and Trademark Office reaffirmed the Patent Trial and Appeal Board’s (“PTAB’s”) previous decision favoring the Broad Institute in the U.S. patent interference involving specific patents for CRISPR/Cas9 editing in human cells between the University of California, the University of …Regulation FD disclosure · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…